IP Library › Granted Patent US 12,194,011
Granted Patent B2
US 12,194,011 · App. 18/089,896 · Granted Jan 14, 2025

Compositions comprising theanine, magnolia, and phellodendron

Inventors: Todd Henderson (Lancaster, SC); David Griffin (Forest Hill, MD); David Bledsoe (Lancaster, SC)
Assignee: Nutramax Laboratories, Inc.
A61K31/198A61K9/0053A61K31/197A61K31/4045A61K31/7076A61K36/575A61K36/756A61K38/018A61K38/38A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,011
App. No.
18/089,896
Granted
Jan 14, 2025
Kind
B2
Abstract

An anxiolytic composition formulated for oral administration to a mammal includes a synergistic combination of L-theanine, at least one of magnolia and an extract of magnolia , and at least one of phellodendron and an extract of phellodendron . The composition may include a combination of an extract of Magnolia officinalis and a extract of Phellodendron amurense . The synergistic combination may provide an anxiolytic change in a release pattern of one or more brain neurotransmitters, such as glutamate and/or γ-aminobutyric acid (GABA).

Claims (20)

1. An anxiolytic composition, comprising a combination of L-theanine, at least one of magnolia and an extract of magnolia , and at least one of phellodendron and an extract of phellodendron in amounts synergistically effective to modulate one or more neurotransmitters.

2. The anxiolytic composition of claim 1 including the extract of magnolia.

3. The anxiolytic composition of claim 2 , wherein the extract of magnolia is an extract of Magnolia officinalis.

4. The anxiolytic composition of claim 3 , wherein the extract of Magnolia officinalis includes at least one of honokiol and magnolol.

5. The anxiolytic composition of claim 1 including the extract of phellodendron.

6. The anxiolytic composition of claim 5 , wherein the extract of phellodendron is an extract of Phellodendron amurense.

7. The anxiolytic composition of claim 6 , wherein the extract of Phellodendron amurense includes berberine.

8. The anxiolytic composition of claim 1 including the extract of magnolia and the extract of phellodendron , wherein the extract of magnolia is an extract of Magnolia officinalis , and the extract of phellodendron is an extract of Phellodendron amurense.

9. The anxiolytic composition of claim 1 , wherein the combination provides an anxiolytic change in a release pattern of one or more neurotransmitters.

10. The anxiolytic composition of claim 9 , wherein the neurotransmitters are brain neurotransmitters selected from the group consisting of glutamate and γ-aminobutyric acid (GABA).

11. The anxiolytic composition of claim 1 including s-adenosylmethionine (SAMe).

12. The anxiolytic composition of claim 11 , wherein the s-adenosylmethionine (SAMe) comprises a SAMe phytate salt.

13. A method for reducing, ameliorating, or treating symptoms of anxiety, comprising administration of a combination of L-theanine, at least one of magnolia and an extract of magnolia , and at least one of phellodendron and an extract of phellodendron in amounts synergistically effective to modulate one or more neurotransmitters.

14. The method of claim 13 , wherein the combination includes the extract of magnolia.

15. The method of claim 14 , wherein the extract of magnolia is an extract of Magnolia officinalis.

16. The method of claim 13 , wherein the combination includes the extract of phellodendron.

17. The method of claim 16 , wherein the extract of phellodendron is an extract of Phellodendron amurense.

18. The method of claim 13 , wherein the combination includes the extract of magnolia and the extract of phellodendron , wherein the extract of magnolia is an extract of Magnolia officinalis , and the extract of phellodendron is an extract of Phellodendron amurense.

19. The method of claim 13 , wherein the combination provides an anxiolytic change in a release pattern of one or more neurotransmitters, and the neurotransmitters are brain neurotransmitters selected from the group consisting of glutamate and γ-aminobutyric acid (GABA).

20. The method of claim 13 , wherein the administration of the combination includes orally administering the combination.

Continuity (6)
Continuation 17157139 · Jan 25, 2021
Continuation 16437701 · Jun 11, 2019
Continuation 15705435 · Sep 15, 2017
Continuation PCTUS2016049630 · Aug 31, 2016
Provisional Application 62212080 · Aug 31, 2015
Related Publication 20230157984A1 · May 25, 2023
References Cited (71)
US 5344648A · Haga et al. · 1994 [cited by applicant]
US 6297280B1 · Ishihara et al. · 2001 [cited by applicant]
US 6316638B1 · Bryans et al. · 2001 [cited by applicant]
US 6582735B2 · Stogniew et al. · 2003 [cited by applicant]
US 6589566B2 · Jeda et al. · 2003 [cited by applicant]
US 6613362B2 · Watson et al. · 2003 [cited by applicant]
US 6814987B2 · Stogniew et al. · 2004 [cited by applicant]
US 6831103B1 · Ueda et al. · 2004 [cited by applicant]
US 7094787B2 · Okubo et al. · 2006 [cited by applicant]
US 7273621B2 · Ozeki et al. · 2007 [cited by applicant]
US 7476406B1 · Smidt · 2009 [cited by applicant]
US 8211674B2 · Okada et al. · 2012 [cited by applicant]
US 8293269B2 · Ozeki et al. · 2012 [cited by applicant]
US 8518458B2 · Bukowski et al. · 2013 [cited by applicant]
US 8597690B2 · Nakamori · 2013 [cited by applicant]
US 8609162B2 · Giuliano et al. · 2013 [cited by applicant]
US 8652545B2 · Nieuwenhuijsen · 2014 [cited by applicant]
US 8741319B2 · Crain et al. · 2014 [cited by applicant]
US 10335384B2 · Henderson et al. · 2019 [cited by applicant]
US 10471088B2 · Giovannone et al. · 2019 [cited by applicant]
US 10940130B2 · Henderson et al. · 2021 [cited by applicant]
US 20020119963A1 · Sanner et al. · 2002 [cited by applicant]
US 20030114536A1 · Han et al. · 2003 [cited by applicant]
US 20040266781A1 · Lowe, III et al. · 2004 [cited by applicant]
US 20080057162A1 · Brucker et al. · 2008 [cited by applicant]
US 20100003351A1 · Jaffe · 2010 [cited by applicant]
US 20100021570A1 · Bieley · 2010 [cited by applicant]
US 20100105697A1 · Bilodeau et al. · 2010 [cited by applicant]
US 20110014277A1 · Bieley · 2011 [cited by applicant]
US 20110159048A1 · Crain et al. · 2011 [cited by applicant]
US 20110223150A1 · Holloway · 2011 [cited by applicant]
US 20110300081A1 · Seneci · 2011 [cited by applicant]
US 20130064803A1 · Naidu et al. · 2013 [cited by applicant]
US 20130064804A1 · Naidu et al. · 2013 [cited by applicant]
US 20130156872A1 · Giuliano et al. · 2013 [cited by applicant]
US 20130156874A1 · Crain et al. · 2013 [cited by applicant]
US 20140243363A1 · Crain et al. · 2014 [cited by applicant]
US 20150125548A1 · Knutsen et al. · 2015 [cited by applicant]
US 20150272989A1 · Roberts et al. · 2015 [cited by applicant]
US 20150320814A1 · Patel et al. · 2015 [cited by applicant]
US 20160271198A1 · Jones et al. · 2016 [cited by applicant]
US 20180169163A1 · Geng · 2018 [cited by applicant]
CA 2459240A1 · 2005 [cited by applicant]
EP 3006026A1 · 2016 [cited by applicant]
JP 2002516312A · 2002 [cited by applicant]
JP 2005511737A · 2005 [cited by applicant]
JP 2006527757A · 2006 [cited by applicant]
JP 2008255123A · 2008 [cited by applicant]
JP 2009500319A · 2009 [cited by applicant]
JP 2009531162A · 2009 [cited by applicant]
JP 2010523567A · 2010 [cited by applicant]
JP 2012206942A · 2012 [cited by applicant]
JP 2015137243A · 2015 [cited by applicant]
JP 6860951B2 · 2021 [cited by applicant]
KR 1020100111935A · 2010 [cited by applicant]
WO 2007004244A1 · 2007 [cited by applicant]
WO 2012050895A1 · 2012 [cited by applicant]
WO 2017040611A1 · 2017 [cited by applicant]
Pure encapsulations retrieved on Jan. 9, 2024 (https://www.pureencapsulationspro.com/relora.html?size=60%20capsules) reference date at Apr. 2008 (Year: 2008). [cited by examiner]
AU Office Action for Application No. 2022203570 dated Mar. 7, 2024 (5 pages). [cited by applicant]
Office Action Mailed for Canadian Application No. 2,995,395, dated May 1, 2023 (2 pages). [cited by applicant]
JP DIV Office Action for Application No. 2022-172193 dated Nov. 7, 2023 (5 pages); English Language Translation (4 pages). [cited by applicant]
Ozeki, Makoto, et al.; The Effects of L-Theanine on Sleep Using the Actigaph; Japanese Journal Physiological Anthropology; 2004; vol. 9, pp. 143-150. [cited by applicant]
Innovation Science and Economic Development Canada, Examination Search Report for CA Application No. 2,995,395, dated Sep. 13, 2022, 3 pages. [cited by applicant]
Decision to Grant a Patent for Japanese Patent Application No. 2021-052019, dated Oct. 4, 2022, 7 pages. [cited by applicant]
Lakhan et al., “Nutritional and Herbal Supplements for Anxiety and Anxiety Related Disorders,” Nutrition J 9(1), 2010, 14 pages. [cited by applicant]
Weeks, “Formulations of Dietary Supplements and Herbal Extracts for Relaxation and Anxiolytic Action,” Medical Science Monitor, 15(11), Nov. 2009, 7 pages. [cited by applicant]
Orosco et al., “Alpha-actalbumin-enriched diets enhance serotonin release and induce anxiolytic and rewarding effects in the rat,” Behavioral Brain Research, vol. 148, No. 1-2, Jan. 1, 2004, 10 pages. [cited by applicant]
Kalman et al., “Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-bind, placebo-controlled clinical trial,” Nutrition Journal, Biomed Central, GB, vol. 7, No. … [cited by applicant]
Nathan et al., “The Neuropharmacology of L-Theanine,” J. of Herbal Pharmacotheraphy (USA), 2006, 9 pages. [cited by applicant]
International Searching Authority, Written Opinion and International Search Report for International Application No. PCT/US2016/049630, mailed on Nov. 17, 2016, 10 pages. [cited by applicant]